Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Taro Pharmaceutical Ind. (NasdaqNM:TARO) -- Ignore unavailable to you. Want to Upgrade?

To: Ed Ajootian who wrote (6)	4/9/2000 8:26:00 PM
From: Sleepman	Respond to of 18

Ed: Good to hear from you. I have continued to be on the BENZ sidelines, but have been wishing you well there. I was speaking to a friend of mine about TARO earlier today. The more I think about this, the more excited I get. Coumadin is a $500million per year market. Dupont (with the branded product) by far has the highest share of the market. There are two or three other players. If Taro succeeds with just 5% of the market share, that will add about 20 million in sales, and alot of that will be profit. That is not too bad for a company whose annual sales are currently 80 or so. That is not taking into account any growth from other areas of their business, like the six or so ANDA's that were approved last year. With the low number of shares outstanding, when this one goes, it should go pretty well. Good Luck. I too am buying at these levels. Dan